Targeting the Expression of Cathepsin B Using CRISPR/Cas9 System in Mammalian Cancer Cells
Targeting the Expression of Cathepsin B Using CRISPR/Cas9 System in Mammalian Cancer Cells
复制标题
DOI：
10.1007/978-1-4939-7595-2_12
复制
发表时间：
2018-01-01
期刊：
影响因子：
--
通讯作者：
Gondi, Christopher S.
中科院分区：
文献类型：
--
作者：
Gnanamony, Manu;Gondi, Christopher S.
组织蛋白酶B属于组织蛋白酶家族，在细胞的正常生理功能中发挥着重要作用。然而，组织蛋白酶B的过度表达与不同的恶性肿瘤有关，这使其成为一个有吸引力的药理靶点。CRISPR-Cas9技术的出现使研究人员能够有效地敲除基因，与早期的方法相比，非特异性活性要低得多。下面描述的方案将使研究人员能够开发组织蛋白酶B基因敲除稳定细胞，并解释研究基因敲除的方法。
Cathepsin B belongs to a family of cathepsins and plays an important role in normal physiological functions in the cell. However, overexpression of cathepsin B has been associated with different malignancies, and this has made it an attractive pharmacological target. The advent of CRISPR-Cas9 technology has allowed researchers to efficiently knock down genes with very less nonspecific activity compared to earlier methods. The protocol described below will enable investigators to develop cathepsin B knockdown stable cells and explains ways to study the knockdown.